Prepared for
Industrial
Hero Finding
Regulatory lock-in is the dominant moat: a vast majority of buyers report filings-based lock-in, and most locked relationships are unlikely to switch.
Health authority filings, qualification burden, and re-validation costs compound to protect incumbent revenue well beyond standard contract terms. Mid-contract switching is rare; competitive dynamics re-emerge only at renewal, where roughly half of buyers evaluate alternatives rather than auto-renew.
Vast majority
Report regulatory lock-in on at least some suppliers
Most
Unlikely to switch under active filings
Vast majority
Expect spending growth over 5 years
Majority
See low-cost-region suppliers as more likely to win RFPs vs. 5 years ago
Study Design
N=169 global decision-makers across biopharma and medtech polymer component procurement.
The sample was scoped to active buyers of single-use polymer components with direct authority over supplier selection, balanced across geography and weighted to the biopharma segment where commercial-stage manufacturing drives the bulk of category spend.
Sample segmentation
Pharma · 70
CDMO · 31
Bioprocess OEM · 14
Medtech OEM · 31
End-user · 9
Other · 14
Interview guide · core topics
- Manufacturer ratings across nine evaluation criteria including quality, price, and innovation
- Product-category leadership across the major single-use component categories
- Share-of-wallet trajectory: position 6 years ago, today, and 5-year forward outlook
- Contract length, regulatory lock-in, switching likelihood, and barriers
- Pricing power, inflation pass-through, and value-for-money perception
- Low-cost-region supplier threat: RFP inclusion, win likelihood, quality parity, and discount thresholds
- Market growth: volume vs. price decomposition, single-use penetration trajectory
Recruit criteria
- Procurement, process engineering, production, or quality roles with supplier selection authority
- Active buyers of single-use polymer components within the past 12 months
- Biopharma manufacturers, CDMOs, bioprocessing OEMs, medtech OEMs, or end-users
- Majority primary decision-makers; meaningful share influencers in the supplier selection process
Key Findings
What the diligence surfaced.
Six signals shaped the deal team's view of the moat, the growth thesis, and the low-cost-region threat.
Vast majority
Regulatory lock-in penetration
Most
Unlikely to switch under filings
Vast majority
Expect 5-year spending growth
Rising
Single-use penetration trajectory over 5 years
Mid-teens %
Median discount required to trigger a switch
Low double-digit %
Median premium justified for a superior supplier
01
The asset leads the most product categories of any single supplier but trails the largest Western incumbent on overall brand.
The single-use polymer supplier is named category leader across a majority of the surveyed product types — more than any peer. The largest Western incumbent holds the #1 overall manufacturer ranking by a narrow margin, driven by stronger innovation perception and brand reputation. Both reach near-universal Good or Excellent ratings on product quality.
02
Regulatory lock-in is the dominant moat and it compounds.
A vast majority of buyers report at least some supplier relationships locked in through health authority filings; a meaningful share are locked on more than half their relationships. Among locked buyers, most are unlikely to switch. Re-validation requirements, qualification burden, and time/cost intensity make mid-contract changes economically unjustifiable for most.
03
Renewal windows are the real competitive battleground.
Most contracts run 3 to 5 years and most buyers will not switch during an active term. At renewal, roughly half evaluate alternatives rather than auto-renew. The competitive dynamics that look frozen mid-contract reopen on a predictable cadence, and quality issues outrank price as the top switching trigger.
04
The market is structurally growing and the volume mix is durable.
A vast majority of buyers expect spending growth over the next 5 years, with most of that growth volume-led rather than price-led, and single-use penetration is projected to keep rising. A majority report polymer spending has outpaced their overall production budget, confirming an adoption tailwind beyond baseline market growth.
05
The low-cost-region supplier threat is real, sized, and bounded.
A majority see low-cost-region suppliers as more likely to win RFPs than 5 years ago, driven by cost competitiveness and quality parity. A vast majority rate low-cost-region price as better, but most still rate brand as weaker. The market estimates a single-digit-to-low-double-digit share of new contracts have shifted in the past two years. About half expect continued downward pricing pressure over the next 3 to 5 years.
06
Pricing position is defensible: a structural asymmetry favors incumbents.
The median justified premium for a demonstrably superior supplier sits in the low double digits, while the median discount needed to trigger a switch sits a few points higher. That asymmetry structurally favors established players. A clear majority view the asset as fairly priced for value delivered, and a vast majority believe innovative products earn a premium.
“The research told us where the moat actually sits. Filings-based lock-in is more durable than the contract length suggests, and the low-cost-region threat is real but bounded by a discount threshold buyers were willing to put a number on.”— Vice President, Global Private Equity Firm
Crosstab · Switching Triggers
What actually moves a buyer at renewal.
Buyers ranked the factors most likely to trigger a supplier switch at contract renewal. Quality outranks price across every region and company type. Reindexed to peak top-2 row = 100. Highlighted row = top trigger.
| Not Likely | Somewhat | Likely | Very Likely | Top-2 | |
|---|---|---|---|---|---|
| Quality issues / consistency | 36 | 69 | 100 | 100 | 100 |
| Pricing pressure | 45 | 88 | 100 | 77 | 89 |
| Supply chain reliability | 55 | 88 | 97 | 77 | 86 |
| Innovation gap with peers | 82 | 100 | 90 | 56 | 71 |
| Regulatory or compliance issue | 100 | 94 | 84 | 56 | 69 |
Indexed · blinded valuesQuality leads top-2 box across the buyer basen=169 buyers globally5-point scale: Not Likely to Very Likely
Heat Map · Lock-In Intensity
Switching barriers compound by buyer segment.
Heat indicates the relative intensity of each barrier as a primary reason buyers in each segment are unlikely to switch mid-contract. Reindexed to peak cell = 100.
| Pharma | CDMO | Bioprocess OEM | Medtech OEM | |
|---|---|---|---|---|
| Re-validation requirements | 94 | 84 | 71 | 68 |
| Qualification burden | 87 | 77 | 68 | 61 |
| Time and cost intensity | 52 | 45 | 35 | 29 |
| Regulatory filing risk | 100 | 89 | 48 | 42 |
Voice of Customer
What polymer component buyers actually said.
Verbatim excerpts from the full quantitative sample, selected for range across regions, company types, and current supplier sets.
CDMO · Solutions Shift
“The major strategic positioning of manufacturers of single-use polymer components is between standardized off-the-shelf products and customized products. We consider the leading supplier to be the best off-the-shelf option in that market that we see.”
— Procurement, Large CDMO
Medtech Supplier · Lock-In
“Switching is highly unlikely due to regulatory lock-ins. Replacing a validated component means re-filing, which is time-consuming and costly.”
— Procurement, Medtech Supplier
Pharma · Quality Premium
“Having product scientists, not just sales reps, is certainly a distinguishing feature, especially during validation.”
— Regulatory, Very Large Pharma Company
Bioprocess OEM · Low-Cost-Region Threat
“I do think the low-cost-region suppliers coming into the market are gonna make a change. We have been dealing with substantially fixed pricing from legacy suppliers, and these competitors are able to adapt and sometimes advance things quickly and undercut pricing.”
— Engineering, Mid-size Bioprocess OEM
CDMO · Solution Bundling
“Over the past five years, the shift has been from just having the product available to a solutions offering that locks its place into the commercialized product into the filing, versus just trying to sell a product.”
— Procurement, Mid-size CDMO
Counter-intuitive
The buyers most locked in are the same buyers most willing to evaluate alternatives at renewal.
The diligence validated the regulatory moat: filings-based lock-in is pervasive, switching mid-contract is rare, and the structural premium versus discount asymmetry favors incumbents. The counter-intuitive finding is that the same buyers who describe lock-in most clearly are also the buyers most likely to evaluate alternatives at renewal. Roughly half will not auto-renew, and the trigger is quality, not price. Lock-in is a moat between renewal windows, not a moat at them, and the next renewal cohort will see active competitive evaluation regardless of how durable the installed base looks today.
Strategic Implications
Three priorities from the diligence.
The research grounded the deal team's view of where the asset needs to invest in the next 12 to 24 months to defend the position and capture the structural growth.
01
Treat renewal windows as the active competitive battleground, not the contract.
Most buyers will not switch mid-contract but roughly half evaluate alternatives at renewal, and quality outranks price as the trigger. Build a renewal-window playbook focused on quality consistency, technical service depth, and pre-renewal account engagement rather than discounting.
02
Close the brand and innovation perception gap with the largest Western incumbent.
The asset leads on product breadth and category count but trails on innovation perception and brand reputation. About half expect AI and advanced modeling tools to widen differentiation. Investing in technical-design leadership is the most defensible path to closing that gap.
03
Defend pricing on the structural premium-to-discount asymmetry; harden quality systems against parity claims.
The median justified premium and the median discount needed to switch are separated by a defensible gap that favors incumbents. The exposure is quality parity claims from low-cost-region suppliers. Reinforce quality systems documentation and audit-readiness as the first line of margin defense.
Success criteria · 12 months
- Maintain category leadership in the majority of surveyed product types across the next 24 months
- Lift overall manufacturer ranking to within a few points of the leading Western incumbent
- Hold mid-contract retention above 95% across the regulated buyer base
- Keep realized price above the median premium threshold across new contracts
Risk register
| Renewal-cycle attrition (about half evaluate alternatives) | HIGH |
| Low-cost-region RFP wins compounding from current base | HIGH |
| Innovation perception gap vs. largest Western incumbent | MED |
| Quality parity claims from lower-cost suppliers | MED |
| Pricing pressure as low-cost-region discount threshold tightens | MED |